Astrazeneca tops expectations in the first quarter on strong cancer drug sales
CAMBRIDGE, Britain — Astrazeneca on Wednesday reported first-quarter profit of $3.08 billion.
The Cambridge, Britain-based company said it had net income of $1.99 cents per share. Earnings, adjusted for non-recurring costs, were $2.58 per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $2.57 per share.
The pharmaceutical posted revenue of $15.29 billion in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $14.96 billion.
Astrazeneca shares have increased almost 2% since the beginning of the year. The stock has increased 34% in the last 12 months.
__
'Democrats say this is a misuse of taxpayer funds' Nassau Republicans awarded over $1 million in taxpayer-funded legal contracts to the one-man law firm of Sheharyar Ali, a longtime GOP ally. Ali's father is an adviser to Nassau County Executive Bruce Blakeman. NewsdayTV's Ken Buffa and Newsday Nassau County politics reporter Bahar Ostadan have the story.
'Democrats say this is a misuse of taxpayer funds' Nassau Republicans awarded over $1 million in taxpayer-funded legal contracts to the one-man law firm of Sheharyar Ali, a longtime GOP ally. Ali's father is an adviser to Nassau County Executive Bruce Blakeman. NewsdayTV's Ken Buffa and Newsday Nassau County politics reporter Bahar Ostadan have the story.
